Lord (Paul) Drayson PhD, Chief Executive Officer of Sensyne Health, said:
“Sensyne is delighted to be working with Cambridge University Hospitals NHS Foundation Trust, a leading national center for the treatment of rare or complex conditions and a university teaching hospital with a worldwide reputation. Cambridge University Hospitals is also recognized as a leader in the use of digital tools and health data to improve patient care and has built a large, high quality data set as a result. The Trust has invested heavily in its digital infrastructure and the curation of its data which means we can start work immediately. Together we aim to use the power of ethical AI to make a real difference in finding new and better ways to treat cancer and other complex diseases.”
Under the agreement, CUH will receive shares in Sensyne, and a royalty from the research undertaken by the clinical AI company under the SRA.
About Cambridge University Hospitals NHS Foundation Trust
Cambridge University Hospitals NHS Foundation Trust (â€œCUHâ€) is one of the largest and best-known trusts in the country, delivering high-quality patient care through Addenbrookeâ€™s and the Rosie Hospitals. CUH is a leading national centre for specialist treatment for rare or complex conditions and a university teaching hospital with a worldwide reputation.
CUH is a key partner in Cambridge University Health Partners (â€œCUHPâ€), one of only six academic health science centres in the UK and is at the heart of the development of the Cambridge Biomedical Campus (â€œCBCâ€), which brings together on one site world-class biomedical research, patient care and education. The Campus is one of the Governmentâ€™s National Institute for Health Research (â€œNIHRâ€) comprehensive biomedical research centres.
About Sensyne Health
Sensyne Health plc (LSE: SENS) is a leading clinical artificial intelligence company operating a unique business model â€“ a for-profit plc making a positive social impact, sharing the financial returns it makes with health systems. The Company applies clinical AI in the healthcare and life science industries. In healthcare, Sensyne delivers remote patient monitoring and real-time decision-making systems for healthcare organizations and their patients. In life sciences, Sensyne analyzes large complex anonymized data sets to help life sciences companies accelerate the development of new medicines.
Back to HCB News